- Home
- MPU vs INKT Comparison
MPU vs INKT Comparison
Compare MPU & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- INKT
- Stock Information
- Founded
- MPU 1989
- INKT 2017
- Country
- MPU Singapore
- INKT United States
- Employees
- MPU N/A
- INKT N/A
- Industry
- MPU Transportation Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- MPU Consumer Discretionary
- INKT Health Care
- Exchange
- MPU Nasdaq
- INKT Nasdaq
- Market Cap
- MPU 78.8M
- INKT 75.7M
- IPO Year
- MPU 1998
- INKT 2021
- Fundamental
- Price
- MPU $2.68
- INKT $18.56
- Analyst Decision
- MPU
- INKT Hold
- Analyst Count
- MPU 0
- INKT 3
- Target Price
- MPU N/A
- INKT $37.50
- AVG Volume (30 Days)
- MPU 1.6M
- INKT 2.9M
- Earning Date
- MPU 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- MPU N/A
- INKT N/A
- EPS Growth
- MPU N/A
- INKT N/A
- EPS
- MPU N/A
- INKT N/A
- Revenue
- MPU $35,228,600.00
- INKT N/A
- Revenue This Year
- MPU N/A
- INKT N/A
- Revenue Next Year
- MPU N/A
- INKT N/A
- P/E Ratio
- MPU N/A
- INKT N/A
- Revenue Growth
- MPU 305.32
- INKT N/A
- 52 Week Low
- MPU $0.49
- INKT $4.56
- 52 Week High
- MPU $2.78
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- MPU 70.42
- INKT 51.35
- Support Level
- MPU $1.82
- INKT $18.54
- Resistance Level
- MPU $2.78
- INKT $21.50
- Average True Range (ATR)
- MPU 0.36
- INKT 8.00
- MACD
- MPU 0.04
- INKT -0.82
- Stochastic Oscillator
- MPU 92.06
- INKT 16.51
About MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.